CSTL - NASDAQ

Castle Biosciences, Inc.

CSTL·NASDAQ

$20.39

+3.4%

HealthcareMedical - Diagnostics & Research

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$618.43M

EPS-0.8300

P/E Ratio-24.57

Earnings Date08/03/2026

578.56M

Assets

3Y+29.0%

5Y+32.0%

10Y+5791.0%

107.68M

Total Liabilities

43%

3Y+124.0%

5Y+356.0%

10Y+347.0%

470.87M

Total Equity

3Y+18.0%

5Y+13.0%

10Y-3399.0%

Castle Biosciences, Inc. Funding & Solvency Profile

CSTL · NASDAQ

Current Assets

Cash & Cash Equivalents116.73M

Net Receivables43.38M

Inventory10.25M

Other Current Assets7.96M

Total Current Assets361 M

Non-Current Assets

Property, Plant & Equipment112.24M

Goodwill & Intangible Assets99.57M

Long-Term Investments0.00

Other Non-Current Assets5.65M

Total Non-Current Assets118 M

Total Assets

578.56M

Financial Health Analysis

Current Ratio

5.26x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.23x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

292 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

62% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Castle Biosciences, Inc. Balance Sheet

CSTL • NASDAQ

Castle Biosciences, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	116.7M	119.7M	98.8M	122.9M	329.6M	409.9M	98.8M	4.5M	1.2M
Short-Term Investments	182.8M	173.4M	144.3M	135.7M	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	299.5M	293.1M	243.1M	258.6M	329.6M	409.9M	98.8M	4.5M	1.2M
Net Receivables	43.4M	51.2M	38.3M	23.5M	17.3M	12.8M	14.6M	12.1M	4.7M
Accounts Receivables	43.4M	51.2M	38.3M	23.5M	17.3M	12.8M	14.6M	12.1M	4.7M
Inventory	10.3M	8.1M	7.9M	4M	2M	2.2M	1.2M	882.2K	304.6K
Prepaids	0.0	0.0	0.0	0.0	4.8M	4.8M	2M	675K	515.5K
Other Current Assets	8M	7.7M	6.3M	6.2M	0.0	0.0	0.0	0.0	0.0
Total Current Assets	361.1M	360.2M	295.6M	292.3M	353.7M	429.6M	116.7M	18.1M	6.7M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	112.2M	62.7M	37.7M	26.5M	16.9M	7.1M	2.1M	1.5M	1.5M
Goodwill	99.6M	10.7M	10.7M	10.7M	0.0	0.0	0.0	0.0	0.0
Intangible Assets	0.0	95.5M	106.6M	115.7M	88.9M	0.0	0.0	4.2K	40.1K
Goodwill & Intangible Assets	99.6M	106.2M	117.3M	126.3M	88.9M	0.0	0.0	4.2K	40.1K
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5M	1.6M
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.5M	-1.6M
Other Non-Current Assets	5.6M	2.1M	2.6M	2.2M	3M	2.6M	1M	2.7M	1.6M
Total Non-Current Assets	217.5M	171.1M	157.7M	155M	108.8M	9.7M	3.1M	4.3M	3.1M
Total Assets	578.6M	531.2M	453.3M	447.3M	462.6M	439.3M	119.7M	22.4M	9.8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	18.7M	8M	10.3M	4.7M	2.5M	2.4M	1.9M	1.5M	1.1M
Accounts Payable	18.7M	6.9M	10.3M	4.7M	2.5M	2.1M	1.9M	1.5M	1.1M
Other Payables	0.0	1.1M	0.0	0.0	0.0	276K	79K	8.4K	0.0
Accrued Expenses	0.0	38.7M	5.6M	3.9M	4.3M	1.9M	1.5M	4.6M	3.1M
Short Term Debt	1.7M	278K	0.0	0.0	0.0	0.0	5.8M	0.0	1M
Capital Lease Obligations (Current)	0.0	1.7M	1.1M	1.8M	1.2M	0.0	0.0	0.0	3.9K
Tax Payables	0.0	1.1M	0.0	37K	695K	276K	79K	8.6K	9.7K
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	6.6M	0.0	0.0	9.7K
Other Current Liabilities	48.2M	774K	30.7M	25.7M	16.9M	10M	6M	706.6K	0.0
Total Current Liabilities	68.7M	49.4M	47.7M	36.1M	24.9M	20.9M	15.3M	6.7M	5.2M
NON-CURRENT LIABILITIES
Long Term Debt	35.2M	9.7M	0.0	0.0	0.0	0.0	19.3M	24.5M	17.6M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	1.7M	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	2.3M	1.6M	206K	428K	635K	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	1.5M	0.0	0.0	0.0	18.3M	1M	55K	1.2M	1.3M
Total Non-Current Liabilities	39M	26M	14.4M	12.1M	25.9M	2.8M	19.3M	25.7M	18.9M
Capital Lease Obligations	0.0	16.3M	15.3M	13.4M	8.2M	0.0	0.0	0.0	3.9K
Total Liabilities	107.7M	75.4M	62.1M	48.2M	50.8M	23.6M	34.6M	32.5M	24.1M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.4M	-809.6K
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	46.5M	36M
Common Stock	30K	28K	27K	27K	25K	25K	17K	1.9K	1.9K
Additional Paid-In Capital	0.0	655.7M	609.5M	560.4M	505.5M	478.2M	137.3M	921K	809.2K
Retained Earnings	-224.3M	-200.1M	-218.4M	-160.9M	-93.8M	-62.5M	-52.2M	-57.5M	-51.1M
Accumulated Other Comprehensive Income/Loss	267K	230K	136K	-381K	0.0	0.0	0.0	-909.4K	-638.5K
Other Total Stockholders' Equity	694.9M	0.0	0.0	0.0	0.0	0.0	0.0	-591.7K	638.1K
Total Stockholders' Equity	470.9M	455.8M	391.3M	399.2M	411.7M	415.7M	85.1M	-10.1M	-14.3M
Total Equity	470.9M	455.8M	391.3M	399.2M	411.7M	415.7M	85.1M	-10.1M	-14.3M
SUMMARY
Total Liabilities & Equity	578.6M	531.2M	453.3M	447.3M	462.6M	439.3M	119.7M	22.4M	9.8M
Total Investments	182.8M	173.4M	144.3M	135.7M	0.0	0.0	0.0	2.5M	1.6M
Total Debt	36.9M	26.3M	15.3M	13.4M	8.2M	0.0	25.1M	24.5M	18.6M
Net Debt	-79.8M	-93.4M	-83.5M	-109.5M	-321.4M	-409.9M	-73.7M	20M	17.4M
Shares Outstanding	29,188,659	29,188,659	29,188,659	29,188,659	29,188,659	29,188,659	29,188,659	29,188,659	29,188,659

SEC Filings

CSTL - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 29, 2026	May 28, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 08, 2026	May 28, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 13, 2026	January 11, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 03, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 03, 2025	November 03, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 08, 2025	August 05, 2025	2025	View Filing

Showing 1 to 10 of 115 filings

Related Guides

Blog Categories

Continue your CSTL research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.